FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:428 July 26, 2007 Number 4

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ullmann, A. J.

Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease . The second sentence of the third paragraph under Efficacy (page 341) should have read "In other analyses, posaconazole was superior to fluconazole in reducing the incidence of proven or probable aspergillosis (odds ratio, 0.31; 95% CI, 0.13 to 0.75; P=0.006) during the treatment period and was superior to fluconazole in reducing the incidence of breakthrough proven or probable invasive fungal infections (odds ratio, 0.30; 95% CI, 0.12 to 0.71; P=0.004) and invasive aspergillosis during the exposure period (odds ratio, 0.17; 95% CI, 0.05 to 0.57; P=0.001)" rather than "invasive aspergillosis during the treatment period." The text has been corrected on the Journal's Web site at www.nejm.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.